# GLP-1 Drugs and Worsening Depression or Anxiety: Results by Molecule

See what a Swedish study of 95,490 people found about worsening mental illness during periods of semaglutide, liraglutide, exenatide and dulaglutide use.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/glp1-mental-illness-by-molecule
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Drugs and Worsening Depression or Anxiety: Results by Molecule

A Swedish study found that periods of semaglutide and liraglutide use were linked to a lower rate of serious psychiatric events or extended psychiatric sick leave.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20265 min readUpdated November 2026

Worsening mental illness vs periods without GLP-1 use · semaglutide · liraglutide · exenatide · dulaglutide · 1.0 — no difference

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A Swedish register study included 95,490 people with depression or anxiety who used an antidiabetic medicine. Of those, 22,480 used a GLP-1 receptor agonist during follow-up.
-   Semaglutide and liraglutide use were associated with lower rates of the study’s combined measure of worsening mental illness.
-   Estimates for exenatide and dulaglutide were uncertain. The study did not include tirzepatide or establish whether GLP-1 medicines treat depression or anxiety.

## What counted as worsening mental illness?

The researchers used Swedish health registers from 2009 through 2022, and the cohort was 59.7% female with a mean age of 50.6 years. It counted four outcomes together: psychiatric hospitalization, more than 14 days of psychiatric sick leave, hospitalization for self-harm, and death by suicide [\[1\]](https://buythisglp.com/research/glp1-mental-illness-by-molecule#ref-1). These records capture serious events and extended work absences. Changes in day-to-day symptoms may occur without any of those events.

The main comparison used periods with each medicine and periods without GLP-1 receptor agonist use in the same person, which helps account for characteristics that stay constant. The [semaglutide dose study](https://buythisglp.com/research/does-a-higher-semaglutide-dose-raise-mental-health-risk) asked a different question by comparing recorded diagnoses among people who reached different doses. These estimates do not establish whether one drug is better than another for mental health.

## What the estimates showed

For the main combined outcome, semaglutide had an adjusted hazard ratio of 0.58 (95% CI 0.51–0.65) and liraglutide 0.82 (0.76–0.89). The estimates were 1.01 (0.69–1.46) for exenatide and 1.01 (0.85–1.20) for dulaglutide. Both of those intervals include 1 and leave room for either lower or higher risk.

Secondary analyses found that periods of semaglutide use were associated with lower risk of worsening depression (0.56, 0.44–0.71), anxiety (0.62, 0.52–0.73), and substance use disorder (0.53, 0.35–0.80). For liraglutide, the detectable association among those three outcomes was for worsening depression (0.74, 0.64–0.87). GLP-1 receptor agonist use as a group was associated with lower risk in a separate analysis of self-harm (0.56, 0.34–0.92) [\[1\]](https://buythisglp.com/research/glp1-mental-illness-by-molecule#ref-1).

Tirzepatide was outside the study

The four estimates apply to the medicines studied. This cohort does not provide a tirzepatide estimate.

## What this study leaves open

Changes over time in other medications, clinical care or symptom severity may still influence the associations. A separate South Korean hospital cohort found more new depression and anxiety diagnoses among Wegovy initiators than among matched non-initiators. It measured different outcomes in a different population. Neither observational study establishes that semaglutide caused the difference in diagnoses or that it treats an existing psychiatric condition [\[2\]](https://buythisglp.com/research/glp1-mental-illness-by-molecule#ref-2).

The Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, and Finnish Ministry of Social Affairs and Health funded the Swedish study. Several authors disclosed relationships with pharmaceutical companies [\[1\]](https://buythisglp.com/research/glp1-mental-illness-by-molecule#ref-1).

For someone taking an antipsychotic, studies on [GLP-1 medicines for antipsychotic-related weight gain](https://buythisglp.com/research/can-you-take-a-glp1-with-antipsychotics) address a separate treatment question about managing weight gain during care.

The [evidence on suicidal thoughts and behavior](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts) includes separate FDA and EMA reviews of suicidality and related events. The FDA requested removal of the suicidal behavior and ideation warning from Wegovy, Saxenda and Zepbound labeling after finding no increased risk in its review [\[3\]](https://buythisglp.com/research/glp1-mental-illness-by-molecule#ref-3). The EMA review of several GLP-1 medicines also found no evidence supporting a causal link with suicidal or self-injurious thoughts and actions [\[4\]](https://buythisglp.com/research/glp1-mental-illness-by-molecule#ref-4). Those reviews address specific safety concerns and do not establish a mental-health treatment effect.

Discuss medication choices and changes in mental health with the clinicians involved in both areas of care.

## Frequently asked

Does semaglutide treat depression?

The Swedish observational study found an association with a lower risk of worsening illness in people with depression or anxiety using an antidiabetic medicine. It did not establish semaglutide as a treatment for depression.

What did the study find for exenatide and dulaglutide?

Each had an adjusted hazard ratio of 1.01. The confidence intervals were consistent with either a lower or a higher risk.

Does this apply to tirzepatide?

The researchers did not evaluate tirzepatide. This study provides no estimate for it.

Who funded the study?

The Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, and Finnish Ministry of Social Affairs and Health funded it. Several authors disclosed relationships with drug companies.

## Sources

1.  \[1\] Taipale H, et al. (2026). Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study The Lancet Psychiatry. [PMID 41862258](https://pubmed.ncbi.nlm.nih.gov/41862258/)
2.  \[2\] Park J, et al. (2026). GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study Diabetes, Obesity and Metabolism. [PMID 42410329](https://pubmed.ncbi.nlm.nih.gov/42410329/)
3.  \[3\] U.S. Food and Drug Administration (2026). FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonists Drug Safety Communication. [Source](https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp)
4.  \[4\] European Medicines Agency (2024). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8–11 April 2024 EMA. [Source](https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
